<DOC>
	<DOCNO>NCT00783588</DOCNO>
	<brief_summary>The study Phase Ib extension trial ass toxicity , tolerability , safety two repeat administration 1x10^8 , 3x10^8 , 1x10^9 autologous Ad-ISF35-transduced CLL B cell give intravenously patient CLL tolerate ISF35 prior Phase I infusion trial M.D . Anderson .</brief_summary>
	<brief_title>A Phase I Extension Trial Repeated Infusions ISF35</brief_title>
	<detailed_description>In previous Phase I clinical trial M.D . Anderson , patient CLL receive intravenous infusion autologous leukemia cell transduce ex vivo adenovirus encode wild-type murine CD154 . This treatment well tolerate without dose-limiting toxicity . Patients experience acute reduction leukemia-cell blood count size enlarge lymph node spleen . The infusion induce change circulate bystander , non-infected CLL cell acute long-term clinical response . The change bystander CLL cell similar observe CLL cell follow ligation CD40 , include enhance de novo expression CD54 , CD80 , CD86 , allow modify CLL cell function effectively present antigen autologous T cell . Following CD40 ligation , CLL cell induce express CD95 DR5 undergo change expression pro- anti-apoptotic protein , ultimately favor apoptosis CLL cell . To build upon result , extension trial complete order ass tolerability repeat infusion ISF35 test whether additional administration enhance anti-leukemic activity exhibit previous Phase I trial .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<criteria>1 . Subjects must enrol tolerated single dose ISF35 MDACC Protocol 20040914 . 2 . Subjects must adequate AdISF35 transduce CLL B cell allow least one additional treatment . 3 . Women childbearing potential ( postmenopausal least one year surgically incapable bear child ) must agree become pregnant duration study . Both men woman participant must agree use contraception duration study . 4 . Subjects must Zubrod performance status ≤ 2 . 5 . Subjects must adequate hematologic , renal , hepatic , coagulation function : Adequate hematologic function : Platelet count ≥ 50,000/μl ; AND Hemoglobin ≥ 10 g/dl ( may support erythropoietin transfusion ) . Adequate renal function : Serum creatinine ≤ 1.5 time upper limit normal ; OR Measured creatinine clearance ≥ 40 mL/min/1.73 m^2 . Adequate hepatic function : Total bilirubin ≤ 2.5 time upper limit normal ; AND ALT ≤ 2.5 time upper limit normal ; AND Adequate coagulation test : Prothrombin time international normalize ratio ( INR ) ≤ 2 ; AND Partial thromboplastin time ≤ 1.66 time upper limit normal 6 . Subjects must give write informed consent Phase 1B extension trial . 1 . Unresolved toxicity ( Grade ≥ 2 ) single administration AddISF35 transduce autologous CLL B cell . 2 . Presence 55 % prolymphocytes . 3 . Chemotherapy ( e.g. , purine analogue , alkylating agent , corticosteroid ) , antibody therapy , immunotherapy , radiation therapy , participation investigational drug treatment within 4 week enrollment protocol time study . 4 . Ongoing toxicity prior antineoplastic therapy . 5 . Prior gene therapy ( EXCEPT AdISF35 ) allogeneic stem cell transplantation . 6 . Untreated autoimmune hemolytic anemia immune thrombocytopenia . 7 . Active infection require parenteral antibiotic . 8 . HIV/HBV/HCV seropositivity . 9 . Uncompensated hypothyroidism ( define TSH great 4x upper limit normal treated replacement hormone ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2008</verification_date>
	<keyword>Chronic lymphocytic leukemia</keyword>
	<keyword>CLL</keyword>
	<keyword>Leukemia</keyword>
	<keyword>Leukemia , Lymphocytic , Chronic , B-Cell</keyword>
	<keyword>Leukemia , B-Cell</keyword>
	<keyword>Immune System Diseases</keyword>
	<keyword>ISF35</keyword>
	<keyword>Ad-ISF35</keyword>
	<keyword>Immunotherapy</keyword>
	<keyword>Immune therapy</keyword>
	<keyword>Active immune therapy</keyword>
</DOC>